Skip to main content

BIB

ETF
—
—

Performance overview

BIB Price
Price Chart

Forward-looking statistics

Beta
1.86
Risk
35.78%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Fund info

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Investing methodPassively Managed
DiversifiedNo
Expense ratio1.16%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNASDAQ
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$0.68
Revenue per share—
Avg trading volume (30 day)$397K
Avg trading volume (10 day)$337K
Put-call ratioN/A

Macro factor sensitivity

Growth+1.6
Credit+6.1
Liquidity+0.4
Inflation-4.2
Commodities-0.4
Interest Rates-2.2

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayJune 25, 2025

News

Take a Look at the Top-Performing Biotech ETFs YTD

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Zacks Investment Research (October 2, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free